Lactulose solution Rx
Generic Name and Formulations:
Lactulose 10g/15mL; soln; for oral or rectal administration.
Various generic manufacturers
Indications for Lactulose solution:
Prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma.
Oral: 30–45mL 3–4 times daily; may adjust dose every day or two to produce 2–3 soft stools daily. Hourly doses of 30–45mL may be used to induce rapid laxation initially; when laxative effect has been achieved, reduce dose to recommended daily dose. Maintenance: continue recommended daily dose. Rectal: may be given as a retention enema via a rectal balloon catheter. Mix 300mL of lactulose solution with 700mL of water or physologic saline, retain for 30–60 minutes. May repeat every 4–6 hours; if evacuated too promptly, may be repeated immediately. Start oral route before stopping enema entirely.
Oral: Individualize dose to produce 2–3 soft stools daily. Infants: initially 2.5–10mL in divided doses. Older children and adolescents: 40–90mL/daily. If initial dose causes diarrhea, reduce dose immediately; discontinue if diarrhea persists.
Patients who require a low galactose diet.
Perform thorough bowel cleansing with non-fermentable solution prior to electrocautery procedures during proctoscopy or colonoscopy. Diabetes. Pregnancy (Cat.B). Nursing mothers.
Avoid concomitant laxatives. Caution with concomitant oral anti-infectives (eg, neomycin); monitor closely. May be antagonized by non-absorbable antacids.
Gas, cramping, diarrhea, nausea, vomiting; infants: also hyponatremia, dehydration.
Formerly known under the brand names Cephulac, Chronulac, Evalose.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|